Evidence map›Paper›PMID 38431689›Full record

Trial reportWorld journal of urology2024

Comparison of mirabegron and vibegron for clinical efficacy and safety in female patients with overactive bladder: a multicenter prospective randomized crossover trial.

Naoki Wada, Mitsuhiro Mizunaga, Noriyuki Abe, Kotona Miyauchi, Shin Kobayashi, Miyu Ohtani, Ryoken Tsunekawa, Masaya Nagabuchi, Shun Morishita, Teppei Ohyama and 9 more

Abstract readRandomized Controlled TrialMulticenter Study
PubMed Publisher
In one paragraph

Trial report in World journal of urology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 2 pooled it
8.6field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 2 syntheses or guidelines pooled it, 16 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Observational
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

19 authors at 6 institutions in 1 country.

Naoki WadaDepartment of Renal and Urologic Surgery, Asahikawa Medical University, 2-1-1-1 Midorigaoka Higashi, Asahikawa, 078-8510, Japan. nwada@asahikawa-med.ac.jp.ORCID http://orcid.org/0000-0002-9587-6798
Mitsuhiro MizunagaNagayama Renal and Urology Clinic, Asahikawa, Japan.
Noriyuki AbeDepartment of Renal and Urologic Surgery, Asahikawa Medical University, 2-1-1-1 Midorigaoka Higashi, Asahikawa, 078-8510, Japan.
Kotona MiyauchiDepartment of Renal and Urologic Surgery, Asahikawa Medical University, 2-1-1-1 Midorigaoka Higashi, Asahikawa, 078-8510, Japan.
Shin KobayashiDepartment of Renal and Urologic Surgery, Asahikawa Medical University, 2-1-1-1 Midorigaoka Higashi, Asahikawa, 078-8510, Japan.
Miyu OhtaniDepartment of Renal and Urologic Surgery, Asahikawa Medical University, 2-1-1-1 Midorigaoka Higashi, Asahikawa, 078-8510, Japan.
Ryoken TsunekawaDepartment of Renal and Urologic Surgery, Asahikawa Medical University, 2-1-1-1 Midorigaoka Higashi, Asahikawa, 078-8510, Japan.
Masaya NagabuchiDepartment of Renal and Urologic Surgery, Asahikawa Medical University, 2-1-1-1 Midorigaoka Higashi, Asahikawa, 078-8510, Japan.
Shun MorishitaDepartment of Renal and Urologic Surgery, Asahikawa Medical University, 2-1-1-1 Midorigaoka Higashi, Asahikawa, 078-8510, Japan.
Teppei OhyamaDepartment of Urology, Kitasaito Hospital, Asahikawa, Japan.
Satoshi YamaguchiDepartment of Urology, Kitasaito Hospital, Asahikawa, Japan.
Hiromichi IuchiDepartment of Urology, Hokushinkai Megumino Hospital, Eniwa, Japan.
Tsuyoshi NodaDepartment of Urology, Fukagawa City Hospital, Fukagawa, Japan.
Yuji SagaDepartment of Urology, Fukagawa City Hospital, Fukagawa, Japan.
Tadasu MotoyaDepartment of Urology, Asahikawa Rehabilitation Hospital, Asahikawa, Japan.
Norihiro KawakamiDepartment of Urology, Asahikawa Rehabilitation Hospital, Asahikawa, Japan.
Masayuki NishiharaNishihara Nephro-Urology Clinic, Rumoi, Japan.
Atsushi NumataDepartment of Urology, Furano Kyokai Hospital, Furano, Japan.
Hidehiro KakizakiDepartment of Renal and Urologic Surgery, Asahikawa Medical University, 2-1-1-1 Midorigaoka Higashi, Asahikawa, 078-8510, Japan.
Asahikawa Medical University · JPFukuyama City Hospital · JPAsahikawa Medical College Hospital · JPAsahikawa University · JPHokuto Hospital · JPOsaka Nishi Clinic · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeTo compare the efficacy and safety of mirabegron and vibegron in female OAB patients.

methodsWe conducted a multicenter, prospective, randomized crossover study of female patients with OAB. The patients were assigned to Group MV (mirabegron for 8 weeks, followed by vibegron for 8 weeks) or group VM (vibegron for 8 weeks, followed by mirabegron for 8 weeks). The primary endpoint was the change in OABSS from baseline, and the secondary endpoint was the change in FVC parameters. After completion of the study, each patient was asked which drug was preferable.

resultsA total of 83 patients were enrolled (40 and 43 in groups MV and VM, respectively). At 8th and 16th week, 33 and 29 in Group MV and 34 and 27 in Group VM continued to receive the treatment. The change in PVR was not significantly different between treatment with mirabegron and vibegron. The changes in OABSS, nighttime frequency, mean, and maximum voided volume were similar between mirabegron and vibegron. The mean change in the daytime frequency was greater in the vibegron than in the mirabegron. Of the 56 patients, 15 (27%) and 30 (53%) preferred mirabegron and vibegron, respectively. The remaining 11 patients (20%) showed no preference. The change in the urgency incontinence score during vibegron was better in patients who preferred vibegron to mirabegron.

conclusionThe efficacies of mirabegron and vibegron in female patients was similar. The patients' preference for vibegron could depend on the efficacy of vibegron for urgency incontinence.

Indexed as

PyrimidinonesPyrrolidinesThiazolesUrinary Bladder, OveractiveUrinary IncontinenceUrological AgentsAcetanilidesAdrenergic beta-3 Receptor AgonistsCross-Over StudiesDouble-Blind MethodFemaleHumansProspective StudiesTreatment OutcomeAcetanilidesAdrenergic beta-3 Receptor AgonistsmirabegronN-(4-((5-(hydroxy(phenyl)methyl)pyrrolidin-2-yl)methyl)phenyl)-4-oxo-4,6,7,8-tetrahydropyrrolo(1,2-a)pyrimidine-6-carboxamidePyrimidinonesPyrrolidinesThiazolesUrological AgentsMirabegronOveractive bladderRandomized studyVibegron

Identifiers

PMID38431689
OpenAlexW4392350172

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.